Physician profile
Stella Ilyaev
NPI 1912907742
$17,714.30
in general payments reported to CMS, 2019-2025
51 companies · $2,488 in 2025
The $2,488 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,735 · 2020: $1,983 · 2021: $2,927 · 2022: $2,278 · 2023: $2,429 · 2024: $2,875 · 2025: $2,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,792.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,791.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,148.48 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,761.06 | 2019-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $1,501.39 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Janssen Pharmaceuticals, INC | $1,047.79 | 2019-2022 | |
| Glaxosmithkline, LLC. | $902.85 | 2019-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $874.77 | 2019-2025 | Mounjaro, Zepbound |
| Amarin Pharma, INC. | $861.61 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $765.88 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $764.20 | 2019-2025 | Evenity, Krystexxa, Repatha |
| Pfizer INC. | $670.40 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $613.80 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $586.25 | 2021-2025 | |
| Novo Nordisk INC | $573.30 | 2019-2025 | Ozempic, Rybelsus |
| Scilex Pharmaceuticals INC. | $557.76 | 2019-2025 | Ztlido |
| Astellas Pharma US INC | $366.75 | 2019-2025 | Veozah |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $301.83 | 2019-2025 | |
| Vanda Pharmaceuticals INC. | $300.05 | 2022-2023 | Hetlioz, Fanapt |
| Aimmune Therapeutics, INC. | $267.68 | 2024-2025 | Zenpep |
| Sumitomo Pharma America, INC. | $232.75 | 2023-2025 | Gemtesa |
| Ardelyx, INC. | $212.21 | 2023-2025 | Ibsrela |
| Dexcom, INC. | $180.34 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Biogen, INC. | $176.60 | 2021-2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $168.66 | 2025 | Symbravo |
| Kowa Pharmaceuticals America, INC. | $165.30 | 2019-2025 | Zoryve, Seglentis, Livalo |
| Ironwood Pharmaceuticals, INC | $128.70 | 2019-2025 | Linzess |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $127.27 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $126.57 | 2019-2024 | Trintellix |
| Horizon Therapeutics Plc | $117.61 | 2019-2023 | Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $115.45 | 2022-2023 | |
| Nestle Healthcare Nutrition INC. | $112.51 | 2020-2023 | |
| Endo Pharmaceuticals INC. | $106.94 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $98.18 | 2020-2023 | Camzyos |
| Abbott Laboratories | $83.90 | 2021-2024 | Freestyle Libre 3 |
| Amneal Pharmaceuticals LLC | $74.66 | 2021-2024 | Unithroid |
| Allergan, INC. | $66.17 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $62.50 | 2023-2024 | Quviviq |
| Optinose US, INC. | $62.26 | 2021 | |
| Exact Sciences Corporation | $56.74 | 2023-2025 | Cologuard Collection Kit |
| Intuity Medical INC | $54.45 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Xeris Pharmaceuticals, INC. | $46.65 | 2021-2024 | Gvoke Hypopen |
| Genentech USA, INC. | $41.79 | 2019-2020 | |
| Smith+Nephew, INC. | $35.35 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $30.64 | 2023-2024 | Nuedexta |
| Recordati_rare_diseases_inc. | $26.79 | 2025 | Isturisa |
| Sunovion Pharmaceuticals INC. | $26.06 | 2022 | |
| Corcept Therapeutics | $22.75 | 2024 | Korlym |
| Ibsa Pharma INC. | $18.50 | 2023 | Tirosint, Licart |
| Avanir Pharmaceuticals, INC. | $18.18 | 2022 | |
| Melinta Therapeutics, LLC | $17.86 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.25 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.86 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stella Ilyaev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.